Corrigendum to “Lenvatinib plus sintilimab versus lenvatinib monotherapy as first-line treatment for advanced HBV-related hepatocellular carcinoma: A retrospective, real-world study” [Heliyon 8 (6) (2022) e09538]
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-11-01
|
| Series: | Heliyon |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2405844022026925 |